Clinical Trials on Supratentorial Gliosarcoma in United States

Total 414 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma

Recurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial Gliosarcoma

United States
Leland Metheny
National Cancer Institute (NCI)

Recruiting

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (hSTAR GBM)

Glioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial Glioblastoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); University of California, Los Angeles; Oncoceutics...

Withdrawn

ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial Gliosarcoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide

Recurrent Glioblastoma | Recurrent Gliosarcoma | Malignant Supratentorial Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Glioblastoma | Gliosarcoma | Supratentorial Glioblastoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Suspended

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Glioblastoma | Gliosarcoma | Supratentorial Glioblastoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Gliosarcoma | Supratentorial Glioblastoma

United States
National Cancer Institute (NCI)
NRG Oncology; Radiation Therapy Oncology Group

Completed

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma | Gliosarcoma | Supratentorial Glioblastoma

United States, Canada, Israel
Lawrence Recht
National Cancer Institute (NCI)

Completed

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Ependymoblastoma | Adult Medulloblastoma | Adult Pineoblastoma | Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) | Adult Oligodendroglial Tumors

United States
Systems Medicine LLC

Unknown

Brostallicin Clinical Trial for Myxoid Liposarcoma (SMI-BRS-202)

Myxoid Liposarcoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor

Untreated Childhood Medulloblastoma | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor

United States
Michael Wagner
Edgewood Oncology Inc.

Not yet recruiting

BTX-A51 in Patients With Liposarcoma

Liposarcoma | MDM2 Gene Amplification | Metastatic Liposarcoma | Unresectable Liposarcoma | Recurrent Liposarcoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Horizon Pharma USA, Inc.

Terminated

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

Myxoid Liposarcoma | Synovial Sarcoma | Round Cell Liposarcoma

United States
The Netherlands Cancer Institute

Unknown

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas (DOREMY)

Myxoid Liposarcoma of Soft Tissue

Netherlands, United Kingdom, Norway, United States, Denmark
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)

Recruiting

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Recurrent Glioblastoma | Newly Diagnosed Glioblastoma | Recurrent Gliosarcoma | Recurrent Astrocytoma, Grade IV | Newly Diagnosed Gliosarcoma | Newly Diagnosed Astrocytoma, Grade IV

United States
M.D. Anderson Cancer Center

Recruiting

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Myxoid/Round Cell Liposarcoma | Synovial Sarcoma

United States
GlaxoSmithKline

Completed

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Neoplasms

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Sarcoma | Soft Tissue Sarcoma | Sarcoma,Soft Tissue | Dedifferentiated Liposarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Unresectable Dedifferentiated Liposarcoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
National Cancer Institute (NCI)

Terminated

Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

Liposarcoma,Myxoid

France, United States, Germany
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); EMD Serono

Terminated

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Liposarcoma | Unresectable Liposarcoma

United States
Fred Hutchinson Cancer Center
Incyte Corporation

Terminated

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Refractory Soft Tissue Sarcoma | Metastatic Leiomyosarcoma | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Advanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Advanced Synovial Sarcoma | Metastatic Chondrosarcoma | Advanced Leiomyosarcoma | Metastatic Myxoid... and other conditions

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Gliosarcoma | Adult Brain Glioblastoma

United States
National Cancer Institute (NCI)

Completed

Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
University of Maryland, Baltimore

Terminated

Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme (GCC 1224)

Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)

United States
National Cancer Institute (NCI)

Completed

Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
GlaxoSmithKline

Active, not recruiting

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Neoplasms

United States, Netherlands, Canada, United Kingdom
University of Colorado, Denver

Completed

Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)

Metastatic Medulloblastoma | High Risk Supratentorial PNET | Metastatic PNET

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa)

Recurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Metastatic Angiosarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Recurrent Angiosarcoma | Refractory Dedifferentiated Liposarcoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Janssen Pharmaceuticals

Withdrawn

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

Myxoid Liposarcoma | Stage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Round Cell Liposarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company

Active, not recruiting

Study of Abemaciclib in Dedifferentiated Liposarcoma

Sarcoma | Dedifferentiated Liposarcoma

United States
Infinity Pharmaceuticals, Inc.

Withdrawn

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Dedifferentiated Liposarcoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent Gliosarcoma

United States
M.D. Anderson Cancer Center

Recruiting

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent Gliosarcoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

Ewing Sarcoma of Bone | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) and other conditions

United States
Gary Archer Ph.D.
National Cancer Institute (NCI); Duke Cancer Institute

Terminated

Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM (INTERCEPT)

Recurrent Glioblastoma | Recurrent Gliosarcoma

United States
Sarcoma Alliance for Research through Collaboration
Eli Lilly and Company

Recruiting

SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

Advanced Dedifferentiated Liposarcoma

United States
Vector Oncology
Novartis

Completed

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Liposarcoma | Surgically Unresectable Liposarcoma | Metastatic Liposarcoma

United States
DNAtrix, Inc.

Completed

DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I)

Glioblastoma or Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma | Giant Cell Glioblastoma | Recurrent Gliosarcoma

United States
Mayo Clinic

Completed

18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma

Ewing Sarcoma of Bone | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Medulloblastoma | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Anaplastic Medulloblastoma | Supratentorial Embryonal Tumor, Not Otherwise Specified

United States, Canada, Australia, Puerto Rico
Center for Neurosciences, Tucson
Genentech, Inc.

Completed

Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme | Recurrent Gliosarcoma

United States

Clinical Trials on Supratentorial Gliosarcoma in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations